Medical industry sponsorship of economic evaluations on new treatments are more likely to be found 'cost-effective' than independent research across a range of diseases,
Jun 22, 2022
0
2
A new research perspective published in Oncoscience by Mikhail Blagosklonny, M.D., Ph.D., looks at the possibility of immediate life extension using rapamycin.
May 11, 2022
0
6
The medical product industry maintains an extensive network of financial and non-financial ties with all major healthcare parties and activities, reveals a study published by The BMJ today.
Nov 3, 2021
0
97
An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and ...
Jun 30, 2021
0
2
Moderna plans to have 100 to 125 million doses of its COVID-19 vaccine available in the first quarter of 2021, the vast majority of which will go to the United States, the biotechnology company announced Thursday.
Dec 4, 2020
0
2
The email that arrived in the ancient German city of Mainz shortly before 1 a.m. in the morning marked a turning point in the global effort to deliver a reliable vaccine against the coronavirus pandemic—and for the little-known ...
Dec 2, 2020
0
2
Cash-strapped Latin American governments face severe geographical, economic and social challenges in trying to ensure life-saving COVID-19 vaccines are made available to vulnerable populations, experts say.
Nov 26, 2020
0
3
The loss of oligodendrocytes (OLs), highly specialized cells of the brain that produce myelin, is a frequent condition in patients suffering neurodegenerative diseases. Myelin is an essential structure that insulates nerve ...
Nov 12, 2020
0
2
Given the global urgency of the COVID-19 pandemic, Microsoft's AI for Health program has stepped in to support the development and potential deployment of Vaxine's COVAX-19 vaccine with a philanthropic grant.
Aug 24, 2020
0
10
With research laboratories around the world racing to develop a coronavirus vaccine, a unique challenge has emerged: how to balance intellectual property rights with serving the public good.
May 29, 2020
0
4
